



**CHRYSOS
CORPORATION**
Assays at the speed of light

Faster, more accurate **gold** analysis


FY26 Financial Results

11 August 2026

Dirk Treasure, Managing Director and CEO

Brett Coventry, CFO

Important notice



The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) ("Chrysos" or the "Group") and is general background information about Chrysos' current activities as at the date of this presentation. The information is given in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with the Company's other announcements to ASX. Information in this presentation, including forecast financial information, should not be considered advice or a recommendation to current shareholders, investors or potential investors, in relation to holding, purchasing or selling securities in the Company, and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation.

Forward-looking statements

This presentation may contain statements that are, or may be deemed to be, forward-looking statements, for example statements that use words such as "may", "will", "would", "could", "expects", "intends", "anticipates", and other similar words that involve risks and uncertainties. You should not place undue reliance on such forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this document, are expected to take place. No person who has made any forward-looking statements in this document has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this document, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company.


This presentation also contains references to certain intentions, expectations and plans of the Company. These intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ.

This presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of this information.

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

To the maximum extent permitted by law, Chrysos, its subsidiaries and their respective officers, employees, agents and consultants, and any other person involved in the preparation of this presentation, disclaim all liability and responsibility, including, without limitation, any liability arising out of fault or negligence, for any direct or indirect loss which may arise from or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

Agenda



FY26 Results presented by Managing Director and CEO, Dirk Treasure, and CFO, Brett Coventry

01 FY26 highlights

Slides 4–8

02 Financial performance

Slides 9–17

03 Growth opportunity

Slides 18–23


04 FY27 guidance and outlook

Slides 24–30

05 Appendices

Slides 31–40

Financial and operating highlights



Achieved higher end of FY26 Revenue and EBITDA guidance

\$88.1m

Total Revenue

- +33% growth YoY versus FY25 (\$66.1m)
- MMAP Revenue of \$62.5m (+12% YoY), AAC Revenue of \$25.5m (+153% YoY)
- **Reflects ongoing global adoption of PhotonAssay™ and strong utilisation**

\$27.2m

EBITDA

- +68% growth YoY FY25 (\$16.1m)
- Improved EBITDA Margin of 31% compared to 24% in FY25
- **Economies of scale and increased utilisation driving profitability**

\$165.9m

Funding position


- Operating cash-flow positive FY26: \$17.9m net inflow
- Funding position includes \$25.9m cash and \$140m in undrawn debt, bolstered by a refinanced debt facility arrangement
- **Well-funded to support increased manufacturing cadence of PhotonAssay™ units**

46

Deployed units


- Seven units deployed in FY26 and six units currently deploying
- 24 new lease agreements signed during FY26, with a further four signed post-period, bringing total contracted units to 87 (including post-period leases)
- **11.3 million samples processed during FY26, up 67% on FY25**

PhotonAssay™ sample volumes



Continued conversion to PhotonAssay™ and industry activity driving samples

PhotonAssay™ Samples Analysed Quarterly



Activity Commentary

- Sustained PhotonAssay™ demand - monthly throughput surpassed a record 1m samples and has held above that level each month since March 2026
- Increased monthly throughput, with year-on-year sample growth of 67%
- Industry outlook remains constructive, supported by an elevated gold market, strong exploration activity and production outlook
- New record of 1.1m+ samples achieved in July 2026


Revenue

- FY26 revenue of \$88.1m, comprised of \$62.5m MMAP and \$25.5m AAC
- AAC represented 29% of revenue, up from 15% in FY25, reflecting the strength of Chrysos’ business model, which captures upside during increased industry activity
- Revenue at the top end of guidance, underpinned by consecutive record sample volumes and achieved in spite of forex headwinds

Sample volumes scaling ahead of the fleet

Rising utilisation, fleet expansion and software-led throughput gains are driving record sample volumes


PhotonAssay™ Samples Analysed Quarterly



Activity Commentary

- Quarterly PhotonAssay™ sample volumes grew ~2.4× over the last 24 months, from ~1.3m in Q4 FY24 to a record ~3.1m samples in Q4 FY26
- Sample growth is outpacing the fleet with hub-lab PhotonAssay™ utilisation increasing from 41% during FY25 to 59% during FY26. Chrysos' global hub labs can support further PhotonAssay™ demand, particularly in EMEA and the Americas:
 - Americas utilisation 27% (FY25) 38% (FY26)
 - APAC utilisation 56% (FY25) 79% (FY26)
 - EMEA utilisation 30% (FY25) 44% (FY26)
- Chrysos deployed 11 units during FY25, seven during FY26 and is currently deploying six units, broadening our global footprint and supporting demand for PhotonAssay™ capacity
- PhotonAssay™ upgrades are increasing per-unit capacity by 10-20% with minimal capital costs. Several units repeatedly demonstrate capacity of almost 50,000 samples per month (nameplate capacity is 40,000pm)

Executing on our global PhotonAssay™ roll out



Strengthening relationships with key miners and laboratories

46 Units Deployed¹




FY26 Activity

- **Seven units deployed in FY26, bringing total deployed units to 46:**
 - Three units deployed with ALS across Australia and Canada
 - One unit deployed for MSA at Grand Falls-Windsor, Canada
 - First unit deployed to South America with Bureau Veritas (BV) in Chile
 - Unit deployed to Norseman, Australia with ITK
 - The first next-generation "XN" unit deployed at SGS Perth
 - Redeploying one Ghanaian unit, demobilised and in transit to Morocco
- **24 new lease agreements and four post-period, contracted units total 87:**
 - Expansion of ALS relationship with four recent agreements in new regions
 - Expanding global footprint with SGS with an upcoming deployment to Canada
 - Expansion of the BV relationship with a unit currently deploying in Kalgoorlie, and two further contracts signed post period for Peru and Mexico
- **Direct-to-mine focus supported by lease agreements with:**
 - A second Newmont unit at their Merian mine, Suriname
 - Acrux Gold's Cononish Project, Scotland
 - Alkane's Bjorkdal mine, Sweden, to be operated by CRS
 - Pantoro's Norseman mine, Australia, operated by ITK
 - Allied Gold's Sadiola mine, West Africa and the Kurmuk mine in Ethiopia
 - Two additional contracts post period with an Australian gold miner

High-quality, growing pipeline will support accelerated deployments

Targeted sales strategy



Increasing utilisation supports sustained gross profit per unit

Two-pronged sales approach

Hub & Spoke Deployment Strategy

Laboratory partnerships support adoption by local miners and explorers.

Sales Managers engage local miners and explorers near hub-and-spoke labs, driving sample volume and PhotonAssay™ adoption.


Higher utilisation drives gross profit, EBITDA margin, and further lab adoption.

Minesite Deployment Strategy

Direct to Mine Deployments bring PhotonAssay™ technology directly to major gold producers, improving mining efficiency with high-quality data.

Our Technical Services Team of metallurgists and geologists offers value-added services - ore body analysis, multi-sample testing, and gold, silver, and copper applications - to maximise the benefits of PhotonAssay™ and drive incremental volume.

Quarterly PhotonAssay™ samples analysed



PhotonAssay™ deployed to hub and spoke laboratories

- Miner adoption supported via endorsement by major lab companies
- Impacted by macro trends with potential volatility in sample volumes

PhotonAssay™ deployed direct to the mine site

- Samples span the breadth of a miner; exploration, mining, processing
- Strong relationships with the miner and upside volume potential




FY26 Financial Summary

Diversifying regional revenues

Continued adoption of PhotonAssay™ and increased industry activity continue to drive growth

Revenue¹ by Region



- Revenue¹ of \$88.1m, up 33% YoY (FY25: \$66.1m), driven by continued adoption of PhotonAssay™ technology and elevated industry activity
- Growth was delivered across all three regions, with APAC up 70% to \$39m, the largest contributor to FY26 growth, driven by three new units and growth of \$11.4m in AAC
- International revenue rose 14% to \$49.2m, or 56% of Group revenue, Americas up 28% to \$23.4m as the installed base scaled, and EMEA up 4% to \$25.8m, consolidating two years of substantial growth
- Group revenue has almost doubled since FY24 (\$45.4m to \$88.1m), underpinned by an increasingly diversified geographic base


Revenue diversification reflects increased global market penetration

1. Revenue includes operating lease and other revenue

Predictable base revenue with accelerating upside

MMAP provides a stable revenue floor, while AAC captures accelerating upside from rising utilisation

MMAP, AAC and Other Revenue




- Minimum Monthly Assay Payments (**MMAP**) provide predictable and sustainable minimum revenue underpinning the business
 - FY26 MMAP of \$62.5m, up 12% on FY25 (\$55.9m)
 - MMAP comprised 71% of FY26 revenue
- Additional Assay Charges (**AAC**) capture per-sample revenue above MMAP, directly linked to customer utilisation
 - FY26 AAC of \$25.5m, up 153% on FY25 (\$10.1m)
 - AAC contributed 29% of FY26 revenue, highlighting the increasing contribution of utilisation-led, per-sample revenue

Further AAC growth expected to continue, amid an elevated gold market and record sample volumes

1. Growth on YoY MMAP/AAC/other revenue

Revenue & profitability



EBITDA margin growing with scale and utilisation


\$'000		FY25	FY26	% change
Revenue		65,990	87,999	
Revenue from consumables		122	111	
Total Revenue	①	66,112	88,110	33%
PhotonAssay™ expenses	②	(15,671)	(21,264)	36%
Other costs		(18)	(52)	
Gross Profit	③	50,423	66,794	32%
Employee expenses		(23,624)	(27,310)	
Travel & marketing costs		(2,484)	(2,690)	
Admin & other expenses		(8,181)	(9,606)	
Total Operating Expenses	④	(34,289)	(39,607)	18%
Insurance recovery income		-	886	
Impairment expense		-	(906)	
EBITDA	⑤	16,134	27,168	69%
D&A		(15,261)	(21,386)	
EBIT		873	5,782	
Net finance, interest & other income		(3,753)	(7,578)	
Loss before income tax	⑥	(2,880)	(1,796)	
Income tax		(5,343)	3,587	
NPAT		(8,223)	1,790	
Other comprehensive income		4,268	(5,421)	
Total comprehensive loss		(3,955)	(3,631)	

- ① **Total Revenue of \$88.1m:** +33% YoY, reflecting continued global adoption of PhotonAssay™, strong gold market conditions and record utilisation across the deployed fleet:
 - **Dependable MMAP Growth:** Consistent increase in MMAP in line with expanding deployments, demonstrating the reliability and strength of Chrysos' business model
 - **Additional Assay Charges Driving Revenue:** Strong gold market conditions and continued market adoption driving materially higher utilisation across the deployed fleet
- ② **PhotonAssay™ Operating Expenses of \$21.3m:** +36% YoY – comprising fleet maintenance of \$11.4m and direct operating labour of \$9.9m; growth reflects a larger deployed fleet and record activity levels, with direct costs held broadly stable at ~24% of revenue
- ③ **Gross profit up 32% to \$66.8m:** (FY25: \$50.4M), with margins steady as PhotonAssay™ cost growth broadly tracked revenue growth
- ④ **Operating Expense Growth of just 18%:** – operating expenses of \$39.6m grew well below the 33% revenue increase; operating costs fell from ~52% to 45% of revenue, evidencing continued scale benefits
- ⑤ **EBITDA Growth of 68% YoY:** Increased to \$27.2m, with the EBITDA margin expanding from 24% to 31% as revenue growth continued to outpace operating cost growth
- ⑥ **Net Profit After Tax (NPAT):** Improvement in underlying earnings and global tax position

Foreign exchange impact on FY26 result

Reported results absorbed a material FX headwind, yet still delivered at the top of guidance

Reported vs constant currency (A\$m)



- FY26 guidance was set in August 2025 on constant-currency FX assumptions, with approximately 55% of Group revenue exposed to non-AUD currencies
- Prior guidance positioned Total Revenue and EBITDA toward the upper end of their ranges (\$80–90m and \$20–27m respectively)
- FY26 delivered at the upper end of guidance: Total Revenue of \$88.1m and EBITDA of \$27.2m
- On a constant-currency basis (August 2025 assumptions), the result equates to ~\$91.0m revenue and ~\$30.2m EBITDA
- The FY26 performance absorbed ~\$2.9m revenue and ~\$3.0m EBITDA FX translation headwind while still delivering at the top of the range, with improving EBITDA conversion


Underlying performance exceeded guidance — reported results absorbed a ~A\$3m FX headwind we actively managed

1. Guidance set in August 2025 with constant currency assumptions (AUD:USD 0.639, AUD:CAD 0.884, AUD:GBP 0.479, AUD:NZD 1.079).

Unit metrics and financial leverage

Strong unit metrics across deployed units

Unit Metrics¹



- Consistent 70-80% gross profit margins sustained across FY24, FY25 and FY26, reflecting durable revenue and disciplined unit cost
- FY26 unit margins held firm even as direct employee costs absorbed short-term incentives (STI) at full achievement of performance, versus partial in prior years
- Cost control supported by hubbing strategy and greater in-house maintenance by Chrysos team members, continuing to reduce reliance on third parties
- Revenue underpinned by MMAP with FY26 MMAP exit rate of \$65.9m
- AAC per unit more than doubled in FY26, supported by broader industry activity and growing market adoption, evidencing revenue upside
- Five units installed in May/June FY25 ramping up revenues from deployment
- Some underperforming units now close to or exceeding committed MMAP volumes allow for future AAC upside

High gross margins of between 70-80% achieved across FY24, FY25 and FY26

1. Based on the average of all deployed units during the period.

Cash flow summary

Operating leverage translating to cash generation

\$000's		FY25	FY26
EBITDA	①	16,134	27,168
Non-Cash Items		4,790	5,280
Changes in Working Cap		(29,756)	(14,519)
Operating Cash flow	②	8,832	17,929
Sustaining Capex		(3,164)	(648)
Growth Capital Expenditure	④	(60,082)	(36,308)
Work-in-progress R&D		(2,908)	(2,041)
Capitalised R&D	③	(2,568)	(2,014)
Total CAPEX		(68,722)	(41,011)
Free Cash flow before financing		(59,890)	(23,082)

- ① **EBITDA Growth:** EBITDA of \$27.2m - a 68% increase from FY25 driven by continued fleet expansion, record sample volumes and the increasing contribution of utilisation-led AAC
- ② **Margin Expansion:** EBITDA margin expanded from 24% to 31% YoY, reflecting the operating leverage inherent in our lease model as the deployed fleet scales
- ③ **Strong Operating Cashflow:** Increased to \$17.9m, up 103% on FY25, reflecting accelerating cash generation. Driven by materially higher EBITDA, effective capital management, improved cash conversion and the ongoing scaling of Chrysos' global operating platform
- ④ **Strategic Growth CAPEX:** \$36.3m invested in global fleet expansion, the core driver of future recurring revenue. Total capital expenditure of \$41.0m includes \$0.6m sustaining capex and R&D (below)
- ⑤ **Continued R&D Investment:** ~\$4.1m R&D (\$2.0m capitalised plus \$2.0m work-in-progress), directed toward infrastructure and next-generation PhotonAssay™ development

Balance sheet

Strong balance sheet provides a solid platform to sustain growth


\$'000	30-Jun-25	30-Jun-26
Assets		
Cash and cash equivalents	21,520	25,892
Trade and other receivables	② 27,707	33,123
Other current assets (incl prepayments)	13,484	15,764
International withholding tax	1,440	3,534
Non-current assets	③ 200,160	228,157
Total Assets	264,310	306,471
Liabilities		
Trade and other payables	34,033	34,723
Other current liabilities	7,052	7,456
Loans and borrowings	④ 17,414	59,445
Other non-current liabilities	7,509	7,169
Total Liabilities	66,008	108,793
Net Assets	198,302	197,678
Issued capital	214,261	215,370
Accumulated losses	(21,945)	(18,684)
Reserves	5,986	992
Total Equity	① 198,302	197,678

- ① Strong Balance Sheet to Support Growth:** Strong balance sheet maintained, with net assets of \$197.7m (FY25: \$198.3m); total assets \$306.5m; \$25.9m cash. Supporting continued global scale-up of the PhotonAssay™ platform
- ② Increased Trade Receivables:** Receivables growth \$33.1m (FY25: \$27.7m), +20%, reflecting increased activity and disciplined collections contributing to positive operating cash flow
- ③ Growth in Non-Current Assets:** Non-current assets will continue to grow, \$228.2m (FY25: \$200.2m), +14%, driven by the expanding PhotonAssay™ fleet, aligning with the company's long-term strategy for increased market penetration and enhanced service delivery
- ④ Debt Facility Utilisation:** \$60.0m drawn of a new \$200m syndicated facility (\$140m undrawn), funding fleet expansion with ample headroom for future deployments

Strengthened funding capacity

Strategic funding to support growth

Increased Funding Position



\$200m Syndicated Facility

- Refinanced corporate facilities via new **three-year A\$200m syndicated facility with three domestic financiers**
- Shift from asset-based financing to a corporate-style structure, designed for **greater operational flexibility**
- Funding headroom +\$105m, reflects lenders' confidence in Chrysos' customer base and long-term contracted revenue
- Improved pricing and covenant package relative to former facility arrangements
- Proceeds drawn to extinguish the existing asset-based facility


Growth Enablement Through FY27 and Beyond

- \$140m in undrawn debt supports manufacturing and global deployment of PhotonAssay™ units
- **Underpins return to target manufacturing cadence of 18 units/year**




Strategy

Growing PhotonAssay™ technology adoption



Expanding market penetration and growing engagement with the world's leading miners

Top 20 gold producing companies by 2025 production



Recent endorsements

- **FY26: Northern Star** became our first mining client to use PhotonAssay™ as its primary analysis technique across all major sites
- **June 2026: Bureau Veritas** deployed our first units to Chile, South America
- **November 2025: SGS**, Perth, installed Chrysos' first next generation "XN" unit
- **August 2025: Bureau Veritas** entered into its first PhotonAssay™ lease. Chrysos now has all four major global geochemistry labs promoting PhotonAssay™
- **May 2025: Newmont Corporation**, the world's leading gold miner, signed an MSA to use PhotonAssay™ for its gold mining projects
- **May 2025: OceanaGold** installed a PhotonAssay™ unit directly to its Macraes mine site in New Zealand


Significant market penetration with 80% of the top 20 gold producers engaged

The Opportunity

Vision: to become the world's leading provider of innovative assay services and technologies

- Convert gold mining projects in all key mining hubs to PhotonAssay™
- Focus on improved customer outcomes to drive sample volumes
- Strategic partnerships with customers that have capacity for larger unit numbers
- Comparative pricing approach for efficient market penetration
- Drive profitability & growth, with a lease model and a high return on capital
- Growth opportunities beyond gold

Total Addressable Market (TAM)¹




1. As of 30th June 2026

Chrysos growth strategy

Disseminated market, now with a presence in every region

Percentage of miners within total addressable market



410 + large¹ global gold mines offer substantial growth opportunity

- Established global footprint for PhotonAssay™ technology supported by major global laboratory partners
- Bureau Veritas agreement supports Chrysos' deployment into South America, with post-period contract signed for Peru, establishing a beachhead in the region
- Chrysos' disseminated target market is well-served via established hubs without incurring substantial expansion costs
- Strategic hubs maximise operational synergies, leading to lower operational costs and sustained gross profit margins

1. Gold mines producing 40,000 pa or more annually (as of 2024)

PhotonAssay™ beyond gold

Unlocking further market opportunities

Core market focus

Additional revenue streams

Near-term R&D


Long-term potential

Non-gold momentum




Current / Core PhotonAssay™ applicability and market focus

Commercially Available Detectable Elements



Increased revenue per sample & sample volume

Optimising Mine Sites
Concurrent moisture & solution analysis




- X-ray fluorescence
- PhotonAssay
- Neutron analysis
- Not geologically relevant

New elements via energy tuning – ~half of the periodic table addressable; two applications in development

- Base & energy metals
- Rare earths
- Neutron analysis (bulk)
- X-ray fluorescence (XRF)
- Automated sample prep

Non-gold samples ('000)



Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26

■ Silver ■ Copper ■ High-grade Total

Non-gold volumes +83% over 18 months

Resilient multi-year growth outlook

Fleet growth, production-linked volumes and a supportive gold price underpin durable earnings



Driver 1 — Fleet scaling

Deployments support ~2x fleet over three years

- Contracted book and deployment pipeline underpin fleet growth
- Pipeline spans manufacturing, shipping, installation and commissioning
- Doubling the installed base expands recurring-revenue capacity



Driver 2 — Resilient demand

Industry maintaining elevated assay cadence

- Structural shift to PhotonAssay™ sustaining elevated sample volumes
- Elevated gold price supports strong customer activity
- Multi-commodity expansion broadens the demand base



Driver 3 — Lower earnings volatility

Volumes linked to production, not exploration


- Revenue tracks processed production volumes, not exploration cycles
- Adoption is sticky — reverting to slower, destructive, lead-based fire assay is an unattractive downgrade
- MMAP contracts provide a recurring revenue floor

A larger fleet, production-linked volumes and a supportive market underpin a resilient, lower-volatility earnings outlook



FY27 Guidance and Outlook

FY26 success derisks FY27



Broad-based industry acceptance across customers, partners and geographies

Pillar 1 — Improving revenue visibility

Contracted pipeline continues to strengthen

- 24 new lease agreements signed during FY26
- 87 contracted units supports (41 to deploy)
- Six units currently being deployed
- Direct-to-mine deployments expanding
- Relationships with the world's biggest miners and labs

Pillar 2 — Existing fleet continues to mature

Utilisation growth complements deployments

- Record sample volumes
- Four consecutive months above one million samples
- Expanding EBITDA margin
- AAC reflects increasing utilisation
- Demonstrated capacity improvements


Pillar 3 — Execution capability strengthened

Operational capability expanded during FY26

- Manufacturing cadence restored
- Strong funding position
- Next Generation PhotonAssay™ progressing
- Global deployment capability expanded
- Increasing use of non-gold analysis

FY27 guidance is supported by a larger contracted fleet, increasing deployment visibility, a mature operating platform and continued utilisation growth across the existing installed base


PhotonAssay™ deployments



Global fleet supporting future growth



PhotonAssay™ deployment pipeline



- Nine units available (pre-shipping, shipping and awaiting installation) – supporting near term deployments
- Six units currently deploying into customer sites
- Five PhotonAssay™ units manufactured since May 2026 trading update
- One redeployment currently underway of the MSA Obuasi unit, which is being redeployed into Morocco
- A further two units deployed since the May 2026 trading update

FY27 Guidance

Forecastable Revenue Model



FY27 Guidance:

- **Total Revenue** range of between \$108m and \$118m
- **EBITDA** range of between \$35m and \$42m

Note: Guidance set in August 2026 with constant currency assumptions (AUD:USD 0.6945 AUD:CAD 0.9627, AUD:GBP 0.522 AUD:EUR 0.6018 AUD:NZD 1.1923 AUD:GHS 8.541)

FY26 in summary

Achieved upper end of FY26 guidance, and well-funded to support future growth

Financial

- Revenue of \$88.1m, up 33% on FY25
- 68% growth in EBITDA to \$27.2m

Operational


- 46 PhotonAssay™ units currently deployed
- Seven units deployed in FY26 with a strong sales and manufacturing pipeline
- 24 new lease agreements signed in FY26 and four post-period, totaling 87 contracted units
- Record (+67% YoY) sample volumes

Corporate

- \$25.9m cash and \$140m in undrawn debt to fund growth. Total funding position of \$165.9m
- Positioned for growth in FY27 and beyond with a targeted manufacturing cadence of 18 units/year



The Chrysos investment proposition



PhotonAssay™ is the mining industry's most innovative assaying solution

Delivering faster, safer, more accurate and environmentally-friendly gold analysis



**Non-discretionary spend
for miners**



Competitive fee-per-sample model



Long-term contracts



Strong patent protection



**Lease model provides secure
revenue with upside potential**



70-80% gross margin

Thank you

For more information, please visit **chrysoscorp.com**
or contact us at **investors@chrysoscorp.com**






Appendix: About Chrysos

Our commercialisation journey

The outcome of 20+ years of research and development



PhotonAssay™ technology

Efficient, effective and environmentally-friendly minerals analysis


Step 1

The crushed sample (2-3 mm) is loaded into jars and scanned into unit by operator



Step 2

Automated high-energy X-ray analysis, activates and detects gold atoms



Step 3

Automated reporting

Sample can be retained for future assay or safely disposed of if no longer required

70 samples per hour
40,000 samples per month



PhotonAssay™ Unit Development

The next generations of Chrysos' PhotonAssay™ analysis

Development focus:

Supply chain
resilience



Improved
performance



Reduced
maintenance

PhotonAssay™- XN: Even greater efficiency

- A new generation of PhotonAssay™ units, representing a smaller unit footprint, lighter weight for ease of installation, improved sample throughput and simplified maintenance
- Strengthened unit economics with lower cost installation, reduced maintenance and higher capacity
- Enhanced supply chain resilience with the introduction of an Australian-designed automation system
- ITK's first Perth unit has had its automation upgraded, demonstrating XN capability and the first complete XN was deployed to SGS Perth during 1H FY26

PhotonAssay™ - XC: The Aussie contender

- Currently in testing and XC-beta design phase
- Automation redesign with a high-performance robot executing the majority of sample handling, providing flexibility to reprogram operations and add additional analysis stages
- Installed as an upgrade to ITK1 unit and operating successfully in Perth since May 2025. Max throughput increased to 83-84 jars p/h
- Modular design with many key components available 'off the shelf' from commercial vendors




Delivering tangible benefits for miners

PhotonAssay™ enables timely decision making and additional gold recovery

The opportunity...

- Each year global miners are estimated to lose >\$2.0 billion worth of recoverable gold
- PhotonAssay™ provides miners with access to real-time data, helping to improve decision making through the value chain
- Enabling the optimisation of processes to generate potential productivity gains

PhotonAssay™ is embedded in the mining value chain




 Denotes PhotonAssay™ value add


PhotonAssay™ Value Add	
Exploration	Fast turnaround for mine planning and scheduling in-pit
Mine	
ROM	Assay-supported blending between pit & processing
Crushing	
Stockpile	Stockpile sampling & optimised gold recovery
Multi-stage concentration	Reduction in process reagents & consumables
Tailings + Water recovery	Tailings grade monitoring
Gold room	All samples retained for QA/QC
Product	Buyer / seller assays

Source: S&P 2020 Global Gold Production

Unit lifecycle & financial profile



Unit economics are the underlying strength behind Chrysos' business



Projected Lifetime Return more than \$20m¹ per unit

1. Based on 3 year average revenue per unit of \$1.95m and average capital cost of FY25 deployed units
2. Based on 3 year average operating costs

Experienced leadership team

Supported by a well-respected and tenured board

Senior leadership team



Dirk Treasure
Founding CEO & Managing Director

- Metallurgist with a background in both technical and commercial mining aspects spanning 20 years in the industry
- 7 years in novel metallurgical process development and commercialisation prior to becoming Chrysos' founding CEO



Brett Coventry
Chief Financial Officer

- Experienced in taking high growth technology start-ups from inception through to maturity
- 20 years in various roles encompassing international expansion, capital raising and listing through IPO

Board of Directors



Rob Adamson – appointed June 2016
Founder & Non-Executive Chairman

- 20+ years' experience in mining and finance
- Executive Chairman of RFC Ambrian



Eric Ford – appointed June 2019
Non-Executive Director

- 40 years of strategic, management, commercial, operating and engineering experience in resources and energy



Elisha Civil – appointed October 2025
Non-Executive Director

- 20+ years' experience across the mining, energy and infrastructure sectors, including senior leadership roles with ASX-listed and government-owned entities



Kerry Gleeson – appointed July 2021
Non-Executive Director

- Experienced executive and non-executive director in mining and associated industries
- Qualified Australian and English Lawyer: M&A, debt & equity funding & commercialising technology




Greg Holt – appointed June 2023
Non-Executive Director

- Senior executive with an international career spanning 40 years across logistics, industrial services, mining contracting and engineering industries



Financial Appendix

Strong tax balance sheet underpinning international growth



Diversified global footprint – operations across ~12 tax jurisdictions


\$11.2m

Closing net deferred tax asset

\$2.97m¹

Current tax expense

A strong tax balance sheet supporting the Group's high-growth trajectory, future earnings and sustainable cash tax profile.



What happened

\$6.6m deferred tax benefit

Deferred tax benefits recognised on Australian tax losses, R&D credits and on transfers of PhotonAssay units overseas.

International growth continued to expand the Group's tax balance sheet.

Cash impact

Cash tax consistent with business growth

Australian taxable income continues to be offset by carried-forward tax losses and R&D tax offsets.

Cash tax reflecting the growth and profitability of international operations.

Future periods

Benefits unwind over time

Deferred tax assets reverse as units depreciate, while new deployments create new differences.

Cash tax to increase as Australian tax attributes are utilised and international operations continue to mature.

1. Primarily driven by taxable profits in established international jurisdictions.

Useful life reassessment extends the depreciation profile

Component useful lives revised – change in accounting estimate effective 1 July 2026

10 → 15 yrs

Weighted average useful life¹

\$18.6m

FY26 deployed unit depreciation

Longer asset lives reduce the annual depreciation charge from FY2027, with no change to cash flow or asset carrying values.

Fleet operating history



Maintenance and failure data



Component-level review



Useful lives extended



Lower depreciation from FY2027

What changed

Component lives extended

Automation: 5 → 10 years
Linear accelerator: 10 → 15 years
Shielding and housing: 20 → 25 years
Other components: 10 → 15 years
Weighted average life: ~10 → 15 years

Accounting treatment

Change in estimate

Applied prospectively from 1 July 2026, with no restatement of FY2026 or comparatives and no change to asset carrying values.
No cash flow or tax depreciation impact, and no impairment indicators.

Modelling implications

Lower charge from FY2027

FY2026 depreciation on deployed units was \$18.6m (closing NBV \$127.2m).
Expected to reduce FY2027 depreciation by approximately \$9m.

1. Approximate weighted average across significant components. Change in accounting estimate under AASB 108, applied prospectively; prior periods not restated.